Literature DB >> 21683401

Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice.

Dae Eun Choi1, Jin Young Jeong, Beom Jin Lim, Yoon-Kyung Chang, Ki-Ryang Na, Young-Tai Shin, Kang Wook Lee.   

Abstract

PURPOSE: Renin-angiotensin system activation is involved in inflammation and fibrosis in the kidney. Aliskiren, a direct renin inhibitor, decreases renin-angiotensin system activation, including plasma renin activity and angiotensin II, but increases the prorenin level, which may promote inflammation and fibrosis in renal tissue. Thus, we evaluated whether inhibiting the renin-angiotensin system by aliskiren would decrease renal inflammation and fibrosis in a mouse model of unilateral ureteral obstruction.
MATERIALS AND METHODS: Ten-week-old male C57BL/6 mice (Samtako, Kyoung Gi-Do, Korea) weighing 30 to 33 gm were divided into 4 groups, including vehicle or aliskiren treated sham operated and vehicle or aliskiren treated unilateral ureteral obstruction groups. We evaluated plasma renin activity, and plasma renin and renal mRNA expression levels of renin and (pro)renin receptor. To evaluate inflammation and fibrosis renal mRNA expression of monocyte chemotactic protein-1, osteopontin and transforming growth factor-β was measured. Hematoxylin and eosin, Masson's trichrome staining, and immunohistochemical staining for CD68, transforming growth factor-β and α-smooth muscle actin were performed.
RESULTS: Plasma renin activity was significantly lower in the aliskiren treated obstruction group than in the vehicle treated obstruction group. Aliskiren treatment increased renal mRNA expression of renin. The number of CD68 positive cells, and renal monocyte chemotactic protein-1 and osteopontin mRNA levels were significantly higher in mice with unilateral ureteral obstruction than in sham operated mice. Aliskiren decreased the increased levels of these inflammation markers. Aliskiren also decreased renal transforming growth factor-β mRNA expression, transforming growth factor-β and α-smooth muscle actin immunostaining, and Masson's trichrome stained areas of unilateral ureteral obstruction kidneys.
CONCLUSIONS: Aliskiren has anti-inflammatory and antifibrotic effects in an experimental unilateral ureteral obstruction mouse model.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683401     DOI: 10.1016/j.juro.2011.03.122

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the inflammasome.

Authors:  Weidong Wang; Renfei Luo; Yu Lin; Feifei Wang; Peili Zheng; Moshe Levi; Tianxin Yang; Chunling Li
Journal:  Am J Physiol Renal Physiol       Date:  2015-02-18

2.  The effect of aliskiren on the renal dysfunction following unilateral ureteral obstruction in the rat.

Authors:  Fayez T Hammad; Loay Lubbad
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-08-05

Review 3.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

4.  Protective Effect of Aliskiren in Experimental Ischemic Stroke: Up-Regulated p-PI3K, p-AKT, Bcl-2 Expression, Attenuated Bax Expression.

Authors:  Jiangyong Miao; Lina Wang; Xiangjian Zhang; Chunhua Zhu; Lili Cui; Hui Ji; Ying Liu; Xiaolu Wang
Journal:  Neurochem Res       Date:  2016-05-14       Impact factor: 3.996

5.  What is the role of renin inhibition during rat septic conditions: preventive effect of aliskiren on sepsis-induced lung injury.

Authors:  Erol Akpinar; Zekai Halici; Elif Cadirci; Yasin Bayir; Emre Karakus; Muhammet Calik; Atilla Topcu; Beyzagul Polat
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-09       Impact factor: 3.000

Review 6.  Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?

Authors:  Kai Song; Qian Li; Xiao-Ya Yin; Ying Lu; Chun-Feng Liu; Li-Fang Hu
Journal:  Oxid Med Cell Longev       Date:  2015-05-11       Impact factor: 6.543

7.  Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.

Authors:  Sungjin Chung; Soojeong Kim; Minyoung Kim; Eun Sil Koh; Seok Joon Shin; Cheol Whee Park; Yoon Sik Chang; Ho-Shik Kim
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

8.  Elevated serum 1,25(OH)2-vitamin D3 level attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction in kl/kl mice.

Authors:  Yujing Sun; Gengyin Zhou; Ting Gui; Aiko Shimokado; Masako Nakanishi; Kosuke Oikawa; Fuyuki Sato; Yasuteru Muragaki
Journal:  Sci Rep       Date:  2014-10-09       Impact factor: 4.379

9.  Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease.

Authors:  Szu-yuan Li; Yung-Tai Chen; Wu-Chang Yang; Der-Cherng Tarng; Chih-Ching Lin; Chih-Yu Yang; Wen-Sheng Liu
Journal:  BMC Nephrol       Date:  2012-08-23       Impact factor: 2.388

10.  Concomitant inhibition of renin angiotensin system and Toll-like receptor 2 attenuates renal injury in unilateral ureteral obstructed mice.

Authors:  Sarah Chung; Jin Young Jeong; Yoon Kyung Chang; Dae Eun Choi; Ki Ryang Na; Beom Jin Lim; Kang Wook Lee
Journal:  Korean J Intern Med       Date:  2016-02-26       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.